PRODUCT LITERATURE

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

---

Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not
tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan
would be eff ective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ
damage.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

-

Specific Detail Info

Lancet 2008; 372: 1174–83

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment